{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T14:50:13Z","timestamp":1785336613800,"version":"3.55.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,8,5]],"date-time":"2021-08-05T00:00:00Z","timestamp":1628121600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,8,5]],"date-time":"2021-08-05T00:00:00Z","timestamp":1628121600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003141","name":"Consejo Nacional de Ciencia y Tecnolog\u00eda","doi-asserted-by":"publisher","award":["262341"],"award-info":[{"award-number":["262341"]}],"id":[{"id":"10.13039\/501100003141","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Malignant Pleural Mesothelioma (MPM) is a rare but aggressive neoplasia that usually presents at advanced stages. Even though some advances have been achieved in the management of patients with MPM, this malignancy continuous to impose a deleterious prognosis for affected patients (12\u201318\u2009months as median survival, and 5\u201310% 5-year survival rate), accordingly, the recognition of biomarkers that allow us to select the most appropriate therapy are necessary.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Immunohistochemistry semi-quantitative analysis was performed to evaluate four different biomarkers (ERCC1, RRM1, RRM2, and hENT-1) with the intent to explore if any of them was useful to predict response to treatment with continuous infusion gemcitabine plus cisplatin. Tissue biopsies from patients with locally advanced or metastatic MPM were analyzed to quantitatively asses the aforementioned biomarkers. Every included patient received treatment with low-dose gemcitabine (250\u2009mg\/m<jats:sup>2<\/jats:sup>) in a 6-h continuous infusion plus cisplatin 35\u2009mg\/m<jats:sup>2<\/jats:sup> on days 1 and 8 every 3 weeks as first-line therapy.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>From the 70 eligible patients, the mean and standard deviation (SD) for ERCC1, RRM1, RRM2 and hENT-1 were 286,178.3 (<jats:bold>\u00b1<\/jats:bold> 219, 019.8); 104,647.1 (<jats:bold>\u00b1<\/jats:bold> 65, 773.4); 4536.5 (<jats:bold>\u00b1<\/jats:bold> 5, 521.3); and 2458.7 (<jats:bold>\u00b1<\/jats:bold> 4, 983.4), respectively. Patients with high expression of RRM1 had an increased median PFS compared with those with lower expression (9.5 vs 4.8\u2009months, <jats:italic>p<\/jats:italic>\u2009=\u2009&lt;\u20090.001). Furthermore, high expression of RRM1 and ERCC1 were associated with an increased median OS compared with their lower expression counterparts; [(23.1 vs 7.2\u2009months for RRM1 <jats:italic>p<\/jats:italic>\u2009=\u2009&lt;\u20090.001) and (17.4 vs 9.8\u2009months for ERCC1 <jats:italic>p<\/jats:italic>\u2009=\u20090.018)].<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>ERCC1 and RRM1 are useful biomarkers that predict better survival outcomes in patients with advanced MPM treated with continuous infusion of gemcitabine plus cisplatin.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12885-021-08287-5","type":"journal-article","created":{"date-parts":[[2021,8,5]],"date-time":"2021-08-05T07:02:51Z","timestamp":1628146971000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["RRM1 and ERCC1 as biomarkers in patients with locally advanced and metastatic malignant pleural mesothelioma treated with continuous infusion of low-dose gemcitabine plus cisplatin"],"prefix":"10.1186","volume":"21","author":[{"given":"Wendy","family":"Mu\u00f1oz-Monta\u00f1o","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sae","family":"Mu\u00f1iz-Hern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejandro","family":"Avil\u00e9s-Salas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodrigo","family":"Catal\u00e1n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis","family":"Lara-Mej\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suraj","family":"Samtani-Bassarmal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andres F.","family":"Cardona","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge","family":"Mendoza-Desi\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Hern\u00e1ndez-Cueto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Altagracia","family":"Maldonado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillermina","family":"Baay-Guzm\u00e1n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Huerta-Yepes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1164-3779","authenticated-orcid":false,"given":"Oscar","family":"Arrieta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,8,5]]},"reference":[{"key":"8287_CR1","doi-asserted-by":"publisher","unstructured":"Tsao AS, Lindwasser OW, Adjei AA, Adusumilli PS, Beyers ML, Blumenthal GM, et al. Current and future management of malignant mesothelioma: a consensus report from the national cancer institute thoracic malignancy steering committee, international association for the study of lung cancer, and mesothelioma applied research foundation. J Thorac Oncol. 2018;13(11):1655\u201367. https:\/\/doi.org\/10.1016\/j.jtho.2018.08.2036.","DOI":"10.1016\/j.jtho.2018.08.2036"},{"issue":"10","key":"8287_CR2","doi-asserted-by":"publisher","first-page":"716","DOI":"10.2471\/BLT.11.086678","volume":"89","author":"V Delgermaa","year":"2011","unstructured":"Delgermaa V, Takahashi K, Park EK, Le GV, Hara T, Sorahan T. Global mesothelioma deaths reported to the world health organization between 1994 and 2008. Bull World Health Organ. 2011;89(10):716\u201324, 24A-24C. https:\/\/doi.org\/10.2471\/BLT.11.086678.","journal-title":"Bull World Health Organ"},{"issue":"3","key":"8287_CR3","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1002\/ajim.20780","volume":"53","author":"G Aguilar-Madrid","year":"2010","unstructured":"Aguilar-Madrid G, Robles-Perez E, Juarez-Perez CA, Alvarado-Cabrero I, Rico-Mendez FG, Javier KG. Case-control study of pleural mesothelioma in workers with social security in Mexico. Am J Ind Med. 2010;53(3):241\u201351. https:\/\/doi.org\/10.1002\/ajim.20780.","journal-title":"Am J Ind Med"},{"key":"8287_CR4","doi-asserted-by":"publisher","unstructured":"Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, Ruffie P, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol. 2003;21(14):2636\u201344. https:\/\/doi.org\/10.1200\/JCO.2003.11.136.","DOI":"10.1200\/JCO.2003.11.136"},{"issue":"5","key":"8287_CR5","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1007\/s00280-014-2429-5","volume":"73","author":"O Arrieta","year":"2014","unstructured":"Arrieta O, Lopez-Macias D, Mendoza-Garcia VO, Bacon-Fonseca L, Munoz-Montano W, Macedo-Perez EO, et al. A phase II trial of prolonged, continuous infusion of low-dose gemcitabine plus cisplatin in patients with advanced malignant pleural mesothelioma. Cancer Chemother Pharmacol. 2014;73(5):975\u201382. https:\/\/doi.org\/10.1007\/s00280-014-2429-5.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"1","key":"8287_CR6","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1200\/JCO.1998.16.1.145","volume":"16","author":"D Curran","year":"1998","unstructured":"Curran D, Sahmoud T, Therasse P, van Meerbeeck J, Postmus PE, Giaccone G. Prognostic factors in patients with pleural mesothelioma: the European organization for research and treatment of cancer experience. J Clin Oncol. 1998;16(1):145\u201352. https:\/\/doi.org\/10.1200\/JCO.1998.16.1.145.","journal-title":"J Clin Oncol"},{"key":"8287_CR7","doi-asserted-by":"publisher","unstructured":"Fennell DA, Parmar A, Shamash J, Evans MT, Sheaff MT, Sylvester R, et al. Statistical validation of the EORTC prognostic model for malignant pleural mesothelioma based on three consecutive phase II trials. J Clin Oncol. 2005;23(1):184\u20139. https:\/\/doi.org\/10.1200\/JCO.2005.07.050.","DOI":"10.1200\/JCO.2005.07.050"},{"issue":"3","key":"8287_CR8","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1378\/chest.113.3.723","volume":"113","author":"JE Herndon","year":"1998","unstructured":"Herndon JE, Green MR, Chahinian AP, Corson JM, Suzuki Y, Vogelzang NJ. Factors predictive of survival among 337 patients with mesothelioma treated between 1984 and 1994 by the Cancer and leukemia group B. Chest. 1998;113(3):723\u201331. https:\/\/doi.org\/10.1378\/chest.113.3.723.","journal-title":"Chest."},{"issue":"16","key":"8287_CR9","doi-asserted-by":"publisher","first-page":"9114","DOI":"10.1016\/S0021-9258(17)39337-7","volume":"260","author":"Y Engstrom","year":"1985","unstructured":"Engstrom Y, Eriksson S, Jildevik I, Skog S, Thelander L, Tribukait B. Cell cycle-dependent expression of mammalian ribonucleotide reductase. Differential regulation of the two subunits. J Biol Chem. 1985;260(16):9114\u20136. https:\/\/doi.org\/10.1016\/S0021-9258(17)39337-7.","journal-title":"J Biol Chem"},{"issue":"6","key":"8287_CR10","doi-asserted-by":"publisher","first-page":"e0126898","DOI":"10.1371\/journal.pone.0126898","volume":"10","author":"MB Choueiri","year":"2015","unstructured":"Choueiri MB, Shen JP, Gross AM, Huang JK, Ideker T, Fanta P. ERCC1 and TS expression as prognostic and predictive biomarkers in metastatic Colon Cancer. PLoS One. 2015;10(6):e0126898. https:\/\/doi.org\/10.1371\/journal.pone.0126898.","journal-title":"PLoS One"},{"key":"8287_CR11","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.cca.2018.05.042","volume":"485","author":"CM Zhu","year":"2018","unstructured":"Zhu CM, Lian XY, Bi YH, Hu CC, Liang YW, Li QS. Prognostic value of ribonucleotide reductase subunit M1 (RRM1) in non-small cell lung cancer: a meta-analysis. Clin Chim Acta. 2018;485:67\u201373. https:\/\/doi.org\/10.1016\/j.cca.2018.05.042.","journal-title":"Clin Chim Acta"},{"issue":"5","key":"8287_CR12","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1097\/MPA.0000000000000807","volume":"46","author":"M Sierzega","year":"2017","unstructured":"Sierzega M, Pach R, Kulig P, Legutko J, Kulig J. Prognostic implications of expression profiling for gemcitabine-related genes (hENT1, dCK, RRM1, RRM2) in patients with Resectable pancreatic adenocarcinoma receiving adjuvant chemotherapy. Pancreas. 2017;46(5):684\u20139. https:\/\/doi.org\/10.1097\/MPA.0000000000000807.","journal-title":"Pancreas."},{"issue":"2","key":"8287_CR13","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1111\/jcpt.12655","volume":"43","author":"QL Han","year":"2018","unstructured":"Han QL, Zhou YH, Lyu Y, Yan H, Dai GH. Effect of ribonucleotide reductase M1 expression on overall survival in patients with pancreatic cancer receiving gemcitabine chemotherapy: a literature-based meta-analysis. J Clin Pharm Ther. 2018;43(2):163\u20139. https:\/\/doi.org\/10.1111\/jcpt.12655.","journal-title":"J Clin Pharm Ther"},{"key":"8287_CR14","doi-asserted-by":"publisher","unstructured":"Liu X, Zhou B, Xue L, Yen F, Chu P, Un F, et al. Ribonucleotide reductase subunits M2 and p53R2 are potential biomarkers for metastasis of colon cancer. Clin Colorectal Cancer. 2007;6(5):374\u201381. https:\/\/doi.org\/10.3816\/CCC.2007.n.007.","DOI":"10.3816\/CCC.2007.n.007"},{"issue":"7","key":"8287_CR15","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1016\/S1470-2045(10)70244-8","volume":"12","author":"LP Jordheim","year":"2011","unstructured":"Jordheim LP, Seve P, Tredan O, Dumontet C. The ribonucleotide reductase large subunit (RRM1) as a predictive factor in patients with cancer. Lancet Oncol. 2011;12(7):693\u2013702. https:\/\/doi.org\/10.1016\/S1470-2045(10)70244-8.","journal-title":"Lancet Oncol"},{"key":"8287_CR16","doi-asserted-by":"publisher","unstructured":"Chen Y, Huang Y, Chen DM, Wu C, Leng QP, Wang WY, et al. RRM1 expression and the clinicopathological characteristics of patients with non-small cell lung cancer treated with gemcitabine. Onco Targets Ther. 2018;11:5579\u201389. https:\/\/doi.org\/10.2147\/OTT.S162667.","DOI":"10.2147\/OTT.S162667"},{"issue":"2","key":"8287_CR17","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1002\/cncr.27739","volume":"119","author":"SB Fisher","year":"2013","unstructured":"Fisher SB, Fisher KE, Patel SH, Lim MG, Kooby DA, El-Rayes BF, et al. Excision repair cross-complementing gene-1, ribonucleotide reductase subunit M1, ribonucleotide reductase subunit M2, and human equilibrative nucleoside transporter-1 expression and prognostic value in biliary tract malignancy. Cancer. 2013;119(2):454\u201362. https:\/\/doi.org\/10.1002\/cncr.27739.","journal-title":"Cancer."},{"key":"8287_CR18","doi-asserted-by":"publisher","unstructured":"Kim R, Tan A, Lai KK, Jiang J, Wang Y, Rybicki LA, et al. Prognostic roles of human equilibrative transporter 1 (hENT-1) and ribonucleoside reductase subunit M1 (RRM1) in resected pancreatic cancer. Cancer. 2011;117(14):3126\u201334. https:\/\/doi.org\/10.1002\/cncr.25883.","DOI":"10.1002\/cncr.25883"},{"key":"8287_CR19","doi-asserted-by":"publisher","unstructured":"Santini D, Vincenzi B, Fratto ME, Perrone G, Lai R, Catalano V, et al. Prognostic role of human equilibrative transporter 1 (hENT1) in patients with resected gastric cancer. J Cell Physiol. 2010;223(2):384\u20138. https:\/\/doi.org\/10.1002\/jcp.22045.","DOI":"10.1002\/jcp.22045"},{"issue":"2","key":"8287_CR20","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1093\/annonc\/mdh059","volume":"15","author":"MJ Byrne","year":"2004","unstructured":"Byrne MJ, Nowak AK. Modified RECIST criteria for assessment of response in malignant pleural mesothelioma. Ann Oncol. 2004;15(2):257\u201360. https:\/\/doi.org\/10.1093\/annonc\/mdh059.","journal-title":"Ann Oncol"},{"issue":"12","key":"8287_CR21","first-page":"6731","volume":"35","author":"ZG Zimling","year":"2015","unstructured":"Zimling ZG, Santoni-Rugiu E, Bech C, Sorensen JB. High RRM1 expression is associated with adverse outcome in patients with cisplatin\/Vinorelbine-treated malignant pleural mesothelioma. Anticancer Res. 2015;35(12):6731\u20138.","journal-title":"Anticancer Res"},{"key":"8287_CR22","doi-asserted-by":"publisher","unstructured":"Zito Marino F, Baselice S, Erra S, Ronchi A, Montella M, Morgillo F, et al. Double-staining immunohistochemistry reveals in malignant pleural mesothelioma the Coexpression of ERCC1 and RRM1 as a frequent biological event related to poorer survival. Appl Immunohistochem Mol Morphol. 2020 Aug 24;Publish Ahead of Print. https:\/\/doi.org\/10.1097\/PAI.0000000000000869. Epub ahead of print. PMID: 32842027.","DOI":"10.1097\/PAI.0000000000000869"},{"key":"8287_CR23","doi-asserted-by":"publisher","unstructured":"Frischknecht L, Meerang M, Soltermann A, Stahel R, Moch H, Seifert B, et al. Importance of excision repair cross-complementation group 1 and ribonucleotide reductase M1 as prognostic biomarkers in malignant pleural mesothelioma treated with platinum-based induction chemotherapy followed by surgery. J Thorac Cardiovasc Surg. 2015;149(6):1539\u201346 e1. https:\/\/doi.org\/10.1016\/j.jtcvs.2015.01.065.","DOI":"10.1016\/j.jtcvs.2015.01.065"},{"key":"8287_CR24","doi-asserted-by":"publisher","unstructured":"Szulkin A, Otv\u00f6s R, Hillerdal CO, Celep A, Yousef-Fadhel E, Skribek H, et al. Characterization and drug sensitivity profiling of primary malignant mesothelioma cells from pleural effusions. BMC Cancer. 2014;24(14):709. https:\/\/doi.org\/10.1186\/1471-2407-14-709 PMID: 25253633; PMCID: PMC4190467.","DOI":"10.1186\/1471-2407-14-709"},{"issue":"1","key":"8287_CR25","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1097\/JTO.0b013e318233d6a9","volume":"7","author":"ZG Zimling","year":"2012","unstructured":"Zimling ZG, Sorensen JB, Gerds TA, Bech C, Andersen CB, Santoni-Rugiu E. Low ERCC1 expression in malignant pleural mesotheliomas treated with cisplatin and vinorelbine predicts prolonged progression-free survival. J Thorac Oncol. 2012;7(1):249\u201356. https:\/\/doi.org\/10.1097\/JTO.0b013e318233d6a9.","journal-title":"J Thorac Oncol"},{"issue":"9","key":"8287_CR26","doi-asserted-by":"publisher","first-page":"1534","DOI":"10.1200\/JCO.2009.25.9275","volume":"28","author":"L Righi","year":"2010","unstructured":"Righi L, Papotti MG, Ceppi P, Bille A, Bacillo E, Molinaro L, et al. Thymidylate synthase but not excision repair cross-complementation group 1 tumor expression predicts outcome in patients with malignant pleural mesothelioma treated with pemetrexed-based chemotherapy. J Clin Oncol. 2010;28(9):1534\u20139. https:\/\/doi.org\/10.1200\/JCO.2009.25.9275.","journal-title":"J Clin Oncol"},{"key":"8287_CR27","doi-asserted-by":"publisher","unstructured":"Zucali PA, Giovannetti E, Destro A, Mencoboni M, Ceresoli GL, Gianoncelli L, et al. Thymidylate synthase and excision repair cross-complementing group-1 as predictors of responsiveness in mesothelioma patients treated with pemetrexed\/carboplatin. Clin Cancer Res. 2011;17(8):2581\u201390. https:\/\/doi.org\/10.1158\/1078-0432.CCR-10-2873.","DOI":"10.1158\/1078-0432.CCR-10-2873"},{"issue":"10","key":"8287_CR28","doi-asserted-by":"publisher","first-page":"4117","DOI":"10.7314\/APJCP.2014.15.10.4117","volume":"15","author":"YB Cihan","year":"2014","unstructured":"Cihan YB, Ozturk A, Arslan A, Deniz K, Baran M, Karaca H. ERCC1 as a biological marker guiding management in malignant pleural mesothelioma. Asian Pac J Cancer Prev. 2014;15(10):4117\u201323. https:\/\/doi.org\/10.7314\/APJCP.2014.15.10.4117.","journal-title":"Asian Pac J Cancer Prev"},{"key":"8287_CR29","doi-asserted-by":"publisher","unstructured":"Kao SC, Lee K, Klebe S, Henderson D, McCaughan B, Vardy J, et al. Excision repair cross complementation group 1 and thymidylate synthase expression in patients with mesothelioma. Clin Lung Cancer. 2013 Mar;14(2):164\u201371. https:\/\/doi.org\/10.1016\/j.cllc.2012.09.003 Epub 2012 Oct 17. PMID: 23085037.","DOI":"10.1016\/j.cllc.2012.09.003"},{"issue":"5","key":"8287_CR30","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1016\/j.cllc.2013.04.013","volume":"14","author":"S Ting","year":"2013","unstructured":"Ting S, Mairinger FD, Hager T, Welter S, Eberhardt WE, Wohlschlaeger J, et al. ERCC1, MLH1, MSH2, MSH6, and \u03b2III-tubulin: resistance proteins associated with response and outcome to platinum-based chemotherapy in malignant pleural mesothelioma. Clin Lung Cancer. 2013;14(5):558\u2013567.e3. https:\/\/doi.org\/10.1016\/j.cllc.2013.04.013 Epub 2013 Jun 27. PMID: 23810210.","journal-title":"Clin Lung Cancer"},{"key":"8287_CR31","doi-asserted-by":"publisher","unstructured":"Powr\u00f3zek T, Kowalski DM, Krawczyk P, Ramlau R, Kucharczyk T, Kalinka-Warzocha E, et al. Correlation between TS, MTHFR, and ERCC1 gene polymorphisms and the efficacy of platinum in combination with pemetrexed first-line chemotherapy in mesothelioma patients. Clin Lung Cancer. 2014;15(6):455\u201365. https:\/\/doi.org\/10.1016\/j.cllc.2014.06.009 Epub 2014 Aug 15. PMID: 25246386.","DOI":"10.1016\/j.cllc.2014.06.009"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-021-08287-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-021-08287-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-021-08287-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,5]],"date-time":"2021-08-05T07:03:08Z","timestamp":1628146988000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-021-08287-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,5]]},"references-count":31,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["8287"],"URL":"https:\/\/doi.org\/10.1186\/s12885-021-08287-5","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,5]]},"assertion":[{"value":"2 November 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 May 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 August 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. The study was conducted in accordance with the Declaration of Helsinki (as revised in 2013). The study was approved by institutional\/regional\/national ethics\/committee\/ethics board of INCan [(010\/056\/ICI) (CEI\/656\/10)] the and individual consent for this retrospective analysis was waived<i>.<\/i>","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"All authors have completed the ICMJE uniform disclosure form.Dr. Oscar Arrieta has received honoraria as an advisor, participated in speakers\u2019 bureau, and given expert opinions to Pfizer, AstraZeneca, Boehringer-Ingelheim, Roche, Lilly, and Bristol-Myers Squibb.The other authors have no conflicts of interest to declare.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"892"}}